2) With increasing long COVID prevalence globally, many clinical trials are investigating potential treatments but confirmative results are still lacking. Over 500 trials have been registered since 2020 with increasing proportion evaluating therapies.
3) Most common interventions studied include exercise, rehabilitation, herbs and pharmaceuticals targeting fatigue, lungs and cognition. Future trials should address underlying mechanisms, standardize definitions and include understudied populations and symptoms.
Thanks ๐
โข โข โข
Missing some Tweet in this thread? You can try to
force a refresh
Plasmacytoid dendritic cells (pDCs) are immune cells that produce type I interferons to fight off viruses ... biorxiv.org/content/10.110โฆ
2) They engulf pathogens, present antigens to activate immune responses, and regulate immune tolerance and inflammation. pDCs play a crucial role in both innate and adaptive immunity.
2) This is a major study that we had already posted and which unfortunately went unnoticed.
We certainly lack the talent to put it forward.
So, we decided to re-write a thread that could be more accessible.
First some explanations.
CELL LINES :ACE2, TMPRSS2 Huh-7, and IGROV-1
3)- ACE2: A549-ACE2 cells are lung carcinoma A549 cells engineered to overexpress the human angiotensin converting enzyme 2 (ACE2) receptor.
- A549-ACE2-TMPRSS2 cells are cells further engineered to overexpress TMPRSS2.
- Huh-7 cells are derived from a human hepatocellular ...
2) This study is first of all about a compartmental model to analyze the complex transmission dynamics of COVID-19, focusing on the Delta and Omicron variants in India. The model tracks disease progression through different population groups.
Factors like ...
3) ... vaccination, time-dependent transmission rates, COVID-19 death rates, loss of vaccine-induced immunity, and transition of asymptomatic cases to recovery are considered.
The model was validated using established epidemiological knowledge and real-world data from India.
2) ... among clinical cultures before and after the COVID-19 pandemic. Most common pathogens studied were Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus. Of 464 AMR results, 18% increased, 15% decreased ...
3) ...67% no change. Gram-negatives made up 69%, with 16% increased AMR, 15% decreased, and 69% no change. Gram-positives were 31%, with 24% increased, 14% decreased, 62% no change AMR.
2) A viral dynamic model was developed to characterize SARS-CoV-2 dynamics based on viral RNA and titer levels from 720 patients with COVID-19 infected with Omicron. The model used a target cell limited approach incorporating non-productive eclipse phase cells, productive cells
3) ...that produce infectious virus which can become non-infectious, and an immune response stimulated by productive cells. Model fitting estimated vaccination delayed time from infection to symptoms from 3.0 to 3.6 days and strengthened the immune effect 1.1-fold.
2) Researchers developed a Newcastle disease virus (NDV)-vectored vaccine expressing the spike protein of SARS-CoV-2 in a pre-fusion stabilized conformation. This chimeric spike protein contains 6 proline substitutions to stabilize it in the pre-fusion state.
3) When delivered intranasally, this NDV-PFS vaccine (expressing the pre-fusion stabilized spike protein) induced robust immune responses in Syrian hamsters and K18 mice.